© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Kiora Pharmaceuticals, Inc. (KPRX) stock surged +1.42%, trading at $3.58 on NASDAQ, up from the previous close of $3.53. The stock opened at $3.58, fluctuating between $3.58 and $3.58 in the recent session.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Employees | 12 |
Beta | -0.29 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) stock price is $3.58 in the last trading session. During the trading session, KPRX stock reached the peak price of $3.58 while $3.58 was the lowest point it dropped to. The percentage change in KPRX stock occurred in the recent session was 1.42% while the dollar amount for the price change in KPRX stock was $0.05.
The NASDAQ listed KPRX is part of Biotechnology industry that operates in the broader Healthcare sector. Kiora Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Stefan Sperl Ph.D.
Executive Vice President of CMC & Operations
Dr. Eric J. Daniels M.B.A., M.D.
Chief Devel. Officer
Ms. Melissa Tosca
Executive Vice President of Fin.
Dr. MaryJane Rafii Ph.D.
Consultant
Dr. Brian M. Strem Ph.D.
Pres, Chief Executive Officer & Director
Ms. Melissa Tosca C.P.A.
Executive Vice President of Fin.
Ms. Melissa Tosca CPA
Executive Vice President of Fin.
KPRX's closing price is 17.33% higher than its 52-week low of $3.00 where as its distance from 52-week high of $8.98 is -60.81%.
Number of KPRX employees currently stands at 12.
Official Website of KPRX is: https://www.kiorapharma.com
KPRX could be contacted at phone 781 788 8869 and can also be accessed through its website. KPRX operates from 1371 East 2100 South, Salt Lake City, UT 84105, United States.
KPRX stock volume for the day was 1.18K shares. The average number of KPRX shares traded daily for last 3 months was 26.03K.
The market value of KPRX currently stands at $10.74M with its latest stock price at $3.58 and 3M of its shares outstanding.